- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01312584
The Effects of Alkalised Cocoa on Human Vascular Function
March 9, 2011 updated by: University of Reading
The Effect of Alkalisation on the Absorption, Metabolism and Vascular Reactivity of Cocoa Flavanols
The primary propose of this study is to determine how processing, in particular alkalisation, alters the vascular effects of high-flavanols foods such as cocoa
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A randomised, triple blind, cross-over design human intervention studies will be conducted in 10 healthy human volunteers to test the impact of alkalisation on the absorption, metabolism and vascular reactivity of cocoa flavanols.
Participants will be requested to consume a standardised high flavanol-rich cocoa, non-alkalised (1745 mg of flavanols), a low-flavanol cocoa, heavily alkalised (1.3 mg of flavanols) and a flavanol-rich cocoa, medium alkalisation (410 mg of flavanols).
The three intervention diets are otherwise matched for macro- and micronutrient content.
Vascular measurements will be performed by using Flow Mediated Dilation (FMD), Laser Doppler imaging (LDI) and Digital Volume Pulse (DVP).
Blood and urine samples will be taken to measure the concentration of flavonoids from the cocoa drinks and markers of blood vessel function.
A number of other biochemical and physiological measures will be recorded including blood glucose, lipoproteins, cytokine levels and blood pressure.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom
- University of Reading
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male
- signed consent form
- age of 18-35 years inclusive
- BMI between 18.5-30
Exclusion Criteria:
- Blood pressure > 150/90 mmHg
- Haemoglobin (anaemia marker) < 125 g/l
- Gamma GT (liver enzymes) > 80 IU/l
- Cholesterol > 6.5 mmol/l
- Had suffered a myocardial infarction or stroke in the previous 12 months
- Suffers from any reproductive disorder
- Suffers from any blood-clotting disorder
- Suffers from any metabolic disorders (e.g. diabetes or any other endocrine or liver diseases)
- Any dietary restrictions or on a weight reducing diet
- Drinking more than 21 units per week
- On any lipid-modifying medication
- On any blood pressure lowering medication
- On any medication affecting blood clotting
- Planning on altering consumption of vitamin supplements/fish oil capsules during the course of the study
- Regular or vigorous exercise (3 times/week, 20 minutes each session)
- Smoking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Non alkalised High Flavanol
Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
|
|
|
Active Comparator: Alkalised high Flavanol
Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
|
|
|
Active Comparator: Alkalised Low Flavanol
Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In vivo circulatory effects relative to a non-alkalised high-flavanol cocoa.
Time Frame: change in Flow Mediated Dilation response between baseline and 2h
|
Flow Mediated Dilation
|
change in Flow Mediated Dilation response between baseline and 2h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeremy Spencer, PhD, University of Reading
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
March 9, 2011
First Submitted That Met QC Criteria
March 9, 2011
First Posted (Estimate)
March 10, 2011
Study Record Updates
Last Update Posted (Estimate)
March 10, 2011
Last Update Submitted That Met QC Criteria
March 9, 2011
Last Verified
November 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UReading-2010-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingCardiovascular Disease (CVD) | Gender Incongruence | Cardiovascular (CV) Risk | Cardiovascular Health Status | Cardiovascular Disease Prevention | Cardiovascular Disease Acute | Cardiovascular Disease Risk FactorItaly
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
University College DublinBeacon Hospital, IrelandRecruitingCoronary Artery Disease (CAD) | Cardiovascular Diseases (CVD) | Cardiovascular Disease Prevention | Cardiovascular Disease Risk FactorIreland
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Istituti Clinici Scientifici Maugeri SpAA.R.C.A Associazioni Regionali Cardiologi AmbulatorialiRecruiting
-
AmgenRecruitingCardiovascular DiseaseItaly, Germany, United States, China, Japan, Spain, Denmark, Australia, France, Canada, Netherlands
-
University of ReadingBiotechnology and Biological Sciences Research Council; Royal Berkshire NHS...Not yet recruiting
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
Clinical Trials on Processed High-flavanol
-
University of NottinghamMars, Inc.CompletedDiabetesUnited Kingdom
-
University of ReadingCompleted
-
Wageningen UniversityTop Institute Food and NutritionCompleted
-
Seoul National University HospitalCompleted
-
University of BirminghamCompletedHealthy | AgeingUnited Kingdom
-
University of Texas at AustinCompleted
-
University of NottinghamMars, Inc.CompletedInsulin ResistanceUnited Kingdom
-
University of California, DavisMars, Inc.Completed
-
University of ReadingCompleted